サマリー

北米の遺伝子合成市場は、2022年から2029年にかけて23.4%の大幅なCAGRを記録すると予測されています。この新しい市場レポートには、歴史的な年である2020年のデータが含まれており、計算の基準年は2021年、予測期間は2022年から2029年です。
市場セグメンテーションを行います：
北米の遺伝子合成市場、コンポーネント別（シンセサイザー、消耗品、ソフトウェア＆サービス）、遺伝子タイプ別（標準遺伝子、発現遺伝子、複合遺伝子、その他）、遺伝子合成タイプ別（遺伝子ライブラリー合成、カスタム遺伝子合成）、用途別（合成生物学、遺伝子工学、ワクチン設計、抗体治療、その他）、方法（固相合成法、CHIP法DNA合成法、PCR法酵素合成法）、エンドユーザー（学術・研究機関、診断研究所、バイオ・製薬会社、その他）、流通チャネル（直接入札、オンライン販売、第三者販売）、国（U.S.,カナダ、メキシコ）産業動向と2029年までの予測
北米の遺伝子合成市場の成長に寄与する主な要因としては、以下のものが挙げられます：

- 慢性感染症の蔓延
- 合成生物学の拡大
- 分子生物学分野での遺伝子合成への関心の高まり
- 遺伝子治療の普及が進む

市場のプレーヤー：

北米の遺伝子合成市場における主要な市場プレイヤーを以下に紹介します：

- サーモフィッシャーサイエンティフィック社
- ゼネラルバイオシステムズ株式会社
- マクロジェン, Co, Ltd
- ボスターバイオロジカルテクノロジー
- クリエイティブバイオジェン
- エキソンビオ
- ツイスト・バイオサイエンス
- オリジェネ・テクノロジーズ・インク
- インテグレーテッド・ディーエヌエー・テクノロジーズ・インク
- ユーロフィンズサイエンティフィック
- NZYTech, Lda.
- アンサ・バイオテクノロジーズ・インク
- ジェンスクリプト
- プロテオジェニクス
- 株式会社バイオベーシック
- ATG：バイオシンセティクスGmbH
- メルクKGaA
- イチョウのバイオワークス
- エボネティクス
- カネカ・ユーロジェンテック S.A
- プロマブ・バイオテクノロジーズ・インク
- シンビオ・テクノロジーズ
- シーエスバイオ
- アゼンタUS, Inc.

ページTOPに戻る

目次

TABLE OF CONTENTS
1 INTRODUCTION 14
1.1 OBJECTIVES OF THE STUDY 14
1.2 MARKET DEFINITION 14
1.3 OVERVIEW OF NORTH AMERICA GENE SYNTHESIS MARKET 14
1.4 CURRENCY AND PRICING 16
1.5 LIMITATION 16
1.6 MARKETS COVERED 17
2 MARKET SEGMENTATION 19
2.1 MARKETS COVERED 19
2.2 GEOGRAPHIC SCOPE 20
2.3 YEARS CONSIDERED FOR THE STUDY 21
2.4 CURRENCY AND PRICING 21
2.5 RESEARCH METHODOLOGY 22
2.6 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 25
2.7 MULTIVARIATE MODELLING 26
2.8 COMPONENT SEGMENT LIFELINE CURVE 26
2.9 DBMR MARKET POSITION GRID 27
2.10 VENDOR SHARE ANALYSIS 29
2.11 MARKET APPLICATION COVERAGE GRID 30
2.12 THE CATEGORY VS TIME GRID 31
2.13 SECONDARY SOURCES 32
2.14 ASSUMPTIONS 32
3 EXECUTIVE SUMMARY 33
4 PREMIUM INSIGHTS 36
4.1 PESTEL 37
4.2 PORTER'S FIVE FORCES MODEL 38
5 NORTH AMERICA GENE SYNTHESIS MARKET: REGULATIONS 39
6 MARKET OVERVIEW 41
6.1 DRIVERS 43
6.1.1 INCREASED PREVALENCE OF CHRONIC INFECTIOUS DISEASES 43
6.1.2 RISING ADOPTION OF GENE THERAPY 43
6.1.3 EXPANSION OF SYNTHETIC BIOLOGY 44
6.1.4 RISING INTEREST OF GENE SYNTHESIS IN THE FIELD OF MOLECULAR BIOLOGY 44
6.2 RESTRAINTS 45
6.2.1 LACK OF TRAINED PROFESSIONALS 45
6.2.2 ETHICAL ISSUES 45
6.2.3 LONG APPROVAL PROCESS 45
6.3 OPPORTUNITIES 46
6.3.1 RISE IN HEALTHCARE EXPENDITURE 46
6.3.2 STRATEGIC INITIATIVES BY KEY PLAYERS 46
6.3.3 RISING DEMAND FOR CUSTOMIZED MEDICATIONS 47
6.4 CHALLENGES 47
6.4.1 TECHNICAL LIMITATIONS ACROSS PRODUCTION PROCESS 47
6.4.2 LACK OF WELL DEFINED PATENT SYSTEM 48
7 NORTH AMERICA GENE SYNTHESIS MARKET, BY COMPONENT 49
7.1 OVERVIEW 50
7.2 SOFTWARE & SERVICES 53
7.3 CONSUMABLES 53
7.3.1 REAGENTS 53
7.3.2 ASSAYS 53
7.3.3 PROBES & DYES 53
7.3.4 OTHERS 53
7.4 SYNTHESIZER 54
7.4.1 COLUMN-BASED SYNTHESIZERS 54
7.4.2 MICROARRAY-BASED SYNTHESIZERS 54
8 NORTH AMERICA GENE SYNTHESIS MARKET, BY GENE TYPE 55
8.1 OVERVIEW 56
8.2 STANDARD GENE 59
8.3 COMPLEX GENE 59
8.4 EXPRESS GENE 59
8.5 OTHERS 59
9 NORTH AMERICA GENE SYNTHESIS MARKET, BY GENE SYNTHESIS TYPE 60
9.1 OVERVIEW 61
9.2 CUSTOM GENE SYNTHESIS 64
9.2.1 STANDARD GENE 64
9.2.2 COMPLEX GENE 64
9.2.3 EXPRESS GENE 64
9.2.4 OTHERS 64
9.3 GENE LIBRARY SYNTHESIS 65
9.3.1 STANDARD GENE 65
9.3.2 COMPLEX GENE 65
9.3.3 EXPRESS GENE 65
9.3.4 OTHERS 65
10 NORTH AMERICA GENE SYNTHESIS MARKET, BY APPLICATION 66
10.1 OVERVIEW 67
10.2 SYNTHETIC BIOLOGY 70
10.2.1 CUSTOM GENE SYNTHESIS 70
10.2.2 GENE LIBRARY SYNTHESIS 70
10.3 GENETIC ENGINEERING 71
10.3.1 CUSTOM GENE SYNTHESIS 71
10.3.2 GENE LIBRARY SYNTHESIS 71
10.4 THERAPEUTIC ANTIBODIES 71
10.4.1 CUSTOM GENE SYNTHESIS 72
10.4.2 GENE LIBRARY SYNTHESIS 72
10.5 VACCINE DESIGN 72
10.5.1 CUSTOM GENE SYNTHESIS 73
10.5.2 GENE LIBRARY SYNTHESIS 73
10.6 OTHERS 74
11 NORTH AMERICA GENE SYNTHESIS MARKET, BY METHOD 75
11.1 OVERVIEW 76
11.2 PCR-BASED ENZYME SYNTHESIS 79
11.3 CHIP-BASED DNA SYNTHESIS 79
11.4 SOLID BASED SYNTHESIS 79
12 NORTH AMERICA GENE SYNTHESIS MARKET, BY END USER 80
12.1 OVERVIEW 81
12.2 ACADEMIC & RESEARCH INSTITUTE 84
12.3 BIOTECH & PHARMACEUTICAL COMPANIES 84
12.4 DIAGNOSTIC LABORATORIES 84
12.5 OTHERS 84
13 NORTH AMERICA GENE SYNTHESIS MARKET, BY DISTRIBUTION CHANNEL 85
13.1 OVERVIEW 86
13.2 DIRECT TENDER 89
13.3 ONLINE DISTRIBUTION 89
13.4 THIRD PARTY DISTRIBUTORS 89
14 NORTH AMERICA GENE SYNTHESIS MARKET,BY REGION 90
14.1 U.S. 95
14.2 CANADA 99
14.3 MEXICO 103
15 NORTH AMERICA GENE SYNTHESIS MARKET: COMPANY LANDSCAPE 107
15.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 107
16 SWOT ANALYSIS 108
17 COMPANY PROFILE 109
17.1 INTEGRATED DNA TECHNOLOGIES, INC. (A SUBSIDIARY OF DANAHER) 109
17.1.1 COMPANY SNAPSHOT 109
17.1.2 COMPANY SHARE ANALYSIS 109
17.1.3 PRODUCT PORTFOLIO 110
17.1.4 RECENT DEVELOPMENTS 110
17.2 THERMO FISHER SCIENTIFIC INC. 111
17.2.1 COMPANY SNAPSHOT 111
17.2.2 REVENUE ANALYSIS 111
17.2.3 COMPANY SHARE ANALYSIS 112
17.2.4 PRODUCT PORTFOLIO 112
17.2.5 RECENT DEVELOPMENT 113
17.3 EUROFINS SCIENTIFIC 114
17.3.1 COMPANY SNAPSHOT 114
17.3.2 REVENUE ANALYSIS 114
17.3.3 COMPANY SHARE ANALYSIS 115
17.3.4 SERVICE PORTFOLIO 115
17.3.5 RECENT DEVELOPMENT 116
17.4 MERCK KGAA 117
17.4.1 COMPANY SNAPSHOT 117
17.4.2 REVENUE ANALYSIS 117
17.4.3 COMPANY SHARE ANALYSIS 118
17.4.4 PRODUCT PORTFOLIO 118
17.4.5 RECENT DEVELOPMENT 119
17.5 KANEKA EUROGENTEC S.A. 120
17.5.1 COMPANY SNAPSHOT 120
17.5.2 REVENUE ANALYSIS 120
17.5.3 COMPANY SHARE ANALYSIS 121
17.5.4 PRODUCT PORTFOLIO 121
17.5.5 RECENT DEVELOPMENTS 122
17.6 ANSA BIOTECHNOLOGIES, INC 123
17.6.1 COMPANY SNAPSHOT 123
17.6.2 PRODUCT PORTFOLIO 123
17.6.3 RECENT DEVELOPMENTS 123
17.7 ATG:BIOSYNTHETICS GMBH 124
17.7.1 COMPANY SNAPSHOT 124
17.7.2 PRODUCT PORTFOLIO 124
17.7.3 RECENT DEVELOPMENTS 124
17.8 AZENTUS US, INC (2021) 125
17.8.1 COMPANY SNAPSHOT 125
17.8.2 REVENUE ANALYSIS 125
17.8.3 PRODUCT PORTFOLIO 126
17.8.4 RECENT DEVELOPMENT 126
17.9 BIO BASIC INC. 128
17.9.1 COMPANY SNAPSHOT 128
17.9.2 PRODUCT PORTFOLIO 128
17.9.3 RECENT DEVELOPMENTS 128
17.10 BOSTER BIOLOGICAL TECHNOLOGY 129
17.10.1 COMPANY SNAPSHOT 129
17.10.2 SERVICE PORTFOLIO 129
17.10.3 RECENT DEVELOPMENT 129
17.11 CSBIO 130
17.11.1 COMPANY SNAPSHOT 130
17.11.2 PRODUCT PORTFOLIO 130
17.11.3 RECENT DEVELOPMENTS 130
17.12 CREATIVE BIOGENE 131
17.12.1 COMPANY SNAPSHOT 131
17.12.2 RODUCTPORTFOLIO 131
17.12.3 RECENT DEVELOPMENT 131
17.13 EVONETIX 132
17.13.1 COMPANY SNAPSHOT 132
17.13.2 PRODUCT PORTFOLIO 132
17.13.3 RECENT DEVELOPMENTS 133
17.14 EXONBIO 134
17.14.1 COMPANY SNAPSHOT 134
17.14.2 PRODUCT PORTFOLIO 134
17.14.3 RECENT DEVELOPMENT 134
17.15 GINKGO BIOWORKS (2021) 135
17.15.1 COMPANY SNAPSHOT 135
17.15.2 REVENUE ANALYSIS 135
17.15.3 PRODUCT PORTFOLIO 136
17.15.4 RECENT DEVELOPMENTS 136
17.16 GENERAL BIOSYSTEMS INC 137
17.16.1 COMPANY SNAPSHOT 137
17.16.2 PRODUCT PORTFOLIO 137
17.16.3 RECENT DEVELOPMENTS 137
17.17 GENSCRIPT 138
17.17.1 COMPANY SNAPSHOT 138
17.17.2 REVENUE ANALYSIS 138
17.17.3 PRODUCT PORTFOLIO 139
17.17.4 RECENT DEVELOPMENTS 139
17.18 MACROGEN CO., LTD. (A SUBSIDIARY OF MACROGEN, INC) 140
17.18.1 COMPANY SNAPSHOT 140
17.18.2 REVENUE ANALYSIS 140
17.18.3 PRODUCT PORTFOLIO 141
17.18.4 RECENT DEVELOPMENTS 141
17.19 NZYTECH, LDA. - GENES AND ENZYMES. 142
17.19.1 COMPANY SNAPSHOT 142
17.19.2 PRODUCT PORTFOLIO 142
17.19.3 RECENT DEVELOPMENT 142
17.20 ORIGENE TECHNOLOGIES, INC 143
17.20.1 COMPANY SNAPSHOT 143
17.20.2 PRODUCT PORTFOLIO 143
17.20.3 RECENT DEVELOPMENTS 143
17.21 PROMAB BIOTECHNOLOGIES 144
17.21.1 COMPANY SNAPSHOT 144
17.21.2 PRODUCT PORTFOLIO 144
17.21.3 RECENT DEVELOPMENTS 144
17.22 PROTEOGENIX 145
17.22.1 COMPANY SNAPSHOT 145
17.22.2 PRODUCT PORTFOLIO 145
17.22.3 RECENT DEVELOPMENTS 145
17.23 SYNBIO TECHNOLOGIES 146
17.23.1 COMPANY SNAPSHOT 146
17.23.2 PRODUCT PORTFOLIO 146
17.23.3 RECENT DEVELOPMENTS 147
17.24 TWIST BIOSCIENCE 148
17.24.1 COMPANY SNAPSHOT 148
17.24.2 REVENUE ANALYSIS 148
17.24.3 PRODUCT PORTFOLIO 149
17.24.4 RECENT DEVELOPMENTS 149
18 QUESTIONNAIRE 150
19 RELATED REPORTS 153

ページTOPに戻る

図表リスト

LIST OF TABLES
TABLE 1 NORTH AMERICA GENE SYNTHESIS MARKET, BY COMPONENT, 2020-2029 (USD MILLION) 52
TABLE 2 NORTH AMERICA CONSUMABLES IN GENE SYNTHESIS MARKET, BY TYPE, 2020-2029 (USD MILLION) 53
TABLE 3 NORTH AMERICA SYNTHESIZER IN GENE SYNTHESIS MARKET, BY TYPE, 2020-2029 (USD MILLION) 54
TABLE 4 NORTH AMERICA GENE SYNTHESIS MARKET, BY GENE TYPE, 2020-2029 (USD MILLION) 58
TABLE 5 NORTH AMERICA GENE SYNTHESIS MARKET, BY GENE SYNTHESIS TYPE, 2020-2029 (USD MILLION) 63
TABLE 6 NORTH AMERICA CUSTOM GENE SYNTHESIS IN GENE SYNTHESIS MARKET, BY GENE TYPE, 2020-2029 (USD MILLION) 64
TABLE 7 NORTH AMERICA GENE LIBRARY SYNTHESIS IN GENE SYNTHESIS MARKET, BY GENE TYPE, 2020-2029 (USD MILLION) 65
TABLE 8 NORTH AMERICA GENE SYNTHESIS MARKET, BY APPLICATION, 2020-2029 (USD MILLION) 69
TABLE 9 NORTH AMERICA SYNTHETIC BIOLOGY IN GENE SYNTHESIS MARKET, BY GENE SYNTHESIS TYPE, 2020-2029 (USD MILLION) 70
TABLE 10 NORTH AMERICA GENETIC ENGINEERING IN GENE SYNTHESIS MARKET, BY GENE SYNTHESIS TYPE, 2020-2029 (USD MILLION) 71
TABLE 11 NORTH AMERICA THERAPEUTIC ANTIBODIES IN GENE SYNTHESIS MARKET, BY GENE SYNTHESIS TYPE, 2020-2029 (USD MILLION) 72
TABLE 12 NORTH AMERICA VACCINE DESIGN IN GENE SYNTHESIS MARKET, BY GENE SYNTHESIS TYPE, 2020-2029 (USD MILLION) 73
TABLE 13 NORTH AMERICA GENE SYNTHESIS MARKET, BY METHOD, 2020-2029 (USD MILLION) 78
TABLE 14 NORTH AMERICA GENE SYNTHESIS MARKET, BY END USER, 2020-2029 (USD MILLION) 83
TABLE 15 NORTH AMERICA GENE SYNTHESIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 88
TABLE 16 U.S. GENE SYNTHESIS MARKET, BY COMPONENT, 2020-2029 (USD MILLION) 95
TABLE 17 U.S. CONSUMABLES IN GENE SYNTHESIS MARKET, BY TYPE, 2020-2029 (USD MILLION) 95
TABLE 18 U.S. SYNTHESIZER IN GENE SYNTHESIS MARKET, BY TYPE, 2020-2029 (USD MILLION) 95
TABLE 19 U.S. GENE SYNTHESIS MARKET, BY GENE TYPE, 2020-2029 (USD MILLION) 95
TABLE 20 U.S. GENE SYNTHESIS MARKET, BY GENE SYNTHESIS TYPE, 2020-2029 (USD MILLION) 96
TABLE 21 U.S. CUSTOM GENE SYNTHESIS IN GENE SYNTHESIS MARKET, BY GENE TYPE, 2020-2029 (USD MILLION) 96
TABLE 22 U.S. GENE LIBRARY SYNTHESIS IN GENE SYNTHESIS MARKET, BY GENE TYPE, 2020-2029 (USD MILLION) 96
TABLE 23 U.S. GENE SYNTHESIS MARKET, BY APPLICATION, 2020-2029 (USD MILLION) 96
TABLE 24 U.S. SYNTHETIC BIOLOGY IN GENE SYNTHESIS MARKET, BY GENE SYNTHESIS TYPE, 2020-2029 (USD MILLION) 97
TABLE 25 U.S. GENETIC ENGINEERING IN GENE SYNTHESIS MARKET, BY GENE SYNTHESIS TYPE, 2020-2029 (USD MILLION) 97
TABLE 26 U.S. THERAPEUTIC ANTIBODIES IN GENE SYNTHESIS MARKET, BY GENE SYNTHESIS TYPE, 2020-2029 (USD MILLION) 97
TABLE 27 U.S. VACCINE DESIGN IN GENE SYNTHESIS MARKET, BY GENE SYNTHESIS TYPE, 2020-2029 (USD MILLION) 97
TABLE 28 U.S. GENE SYNTHESIS MARKET, BY METHOD, 2020-2029 (USD MILLION) 98
TABLE 29 U.S. GENE SYNTHESIS MARKET, BY END USER, 2020-2029 (USD MILLION) 98
TABLE 30 U.S. GENE SYNTHESIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 98
TABLE 31 CANADA GENE SYNTHESIS MARKET, BY COMPONENT, 2020-2029 (USD MILLION) 99
TABLE 32 CANADA CONSUMABLES IN GENE SYNTHESIS MARKET, BY TYPE, 2020-2029 (USD MILLION) 99
TABLE 33 CANADA SYNTHESIZER IN GENE SYNTHESIS MARKET, BY TYPE, 2020-2029 (USD MILLION) 99
TABLE 34 CANADA GENE SYNTHESIS MARKET, BY GENE TYPE, 2020-2029 (USD MILLION) 99
TABLE 35 CANADA GENE SYNTHESIS MARKET, BY GENE SYNTHESIS TYPE, 2020-2029 (USD MILLION) 100
TABLE 36 CANADA CUSTOM GENE SYNTHESIS IN GENE SYNTHESIS MARKET, BY GENE TYPE, 2020-2029 (USD MILLION) 100
TABLE 37 CANADA GENE LIBRARY SYNTHESIS IN GENE SYNTHESIS MARKET, BY GENE TYPE, 2020-2029 (USD MILLION) 100
TABLE 38 CANADA GENE SYNTHESIS MARKET, BY APPLICATION, 2020-2029 (USD MILLION) 100
TABLE 39 CANADA SYNTHETIC BIOLOGY IN GENE SYNTHESIS MARKET, BY GENE SYNTHESIS TYPE, 2020-2029 (USD MILLION) 101
TABLE 40 CANADA GENETIC ENGINEERING IN GENE SYNTHESIS MARKET, BY GENE SYNTHESIS TYPE, 2020-2029 (USD MILLION) 101
TABLE 41 CANADA THERAPEUTIC ANTIBODIES IN GENE SYNTHESIS MARKET, BY GENE SYNTHESIS TYPE, 2020-2029 (USD MILLION) 101
TABLE 42 CANADA VACCINE DESIGN IN GENE SYNTHESIS MARKET, BY GENE SYNTHESIS TYPE, 2020-2029 (USD MILLION) 101
TABLE 43 CANADA GENE SYNTHESIS MARKET, BY METHOD, 2020-2029 (USD MILLION) 102
TABLE 44 CANADA GENE SYNTHESIS MARKET, BY END USER, 2020-2029 (USD MILLION) 102
TABLE 45 CANADA GENE SYNTHESIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 102
TABLE 46 MEXICO GENE SYNTHESIS MARKET, BY COMPONENT, 2020-2029 (USD MILLION) 103
TABLE 47 MEXICO CONSUMABLES IN GENE SYNTHESIS MARKET, BY TYPE, 2020-2029 (USD MILLION) 103
TABLE 48 MEXICO SYNTHESIZER IN GENE SYNTHESIS MARKET, BY TYPE, 2020-2029 (USD MILLION) 103
TABLE 49 MEXICO GENE SYNTHESIS MARKET, BY GENE TYPE, 2020-2029 (USD MILLION) 103
TABLE 50 MEXICO GENE SYNTHESIS MARKET, BY GENE SYNTHESIS TYPE, 2020-2029 (USD MILLION) 104
TABLE 51 MEXICO CUSTOM GENE SYNTHESIS IN GENE SYNTHESIS MARKET, BY GENE TYPE, 2020-2029 (USD MILLION) 104
TABLE 52 MEXICO GENE LIBRARY SYNTHESIS IN GENE SYNTHESIS MARKET, BY GENE TYPE, 2020-2029 (USD MILLION) 104
TABLE 53 MEXICO GENE SYNTHESIS MARKET, BY APPLICATION, 2020-2029 (USD MILLION) 104
TABLE 54 MEXICO SYNTHETIC BIOLOGY IN GENE SYNTHESIS MARKET, BY GENE SYNTHESIS TYPE, 2020-2029 (USD MILLION) 105
TABLE 55 MEXICO GENETIC ENGINEERING IN GENE SYNTHESIS MARKET, BY GENE SYNTHESIS TYPE, 2020-2029 (USD MILLION) 105
TABLE 56 MEXICO THERAPEUTIC ANTIBODIES IN GENE SYNTHESIS MARKET, BY GENE SYNTHESIS TYPE, 2020-2029 (USD MILLION) 105
TABLE 57 MEXICO VACCINE DESIGN IN GENE SYNTHESIS MARKET, BY GENE SYNTHESIS TYPE, 2020-2029 (USD MILLION) 105
TABLE 58 MEXICO GENE SYNTHESIS MARKET, BY METHOD, 2020-2029 (USD MILLION) 106
TABLE 59 MEXICO GENE SYNTHESIS MARKET, BY END USER, 2020-2029 (USD MILLION) 106
TABLE 60 MEXICO GENE SYNTHESIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 106